FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

VIIIEO 1	AND EXCHANGE COMMISSIN
	D 0 00540

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(0). 0	ee instruction	10.																		
Name and Address of Reporting Person* Howe Jill Ann						2. Issuer Name and Ticker or Trading Symbol Lineage Cell Therapeutics, Inc. [LCTX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Howe Jill Allil															Direc			10% Ov		
,					<u> </u>									V	Office below	er (give title		Other (s	pecify	
(Last)	(F		Date of Earliest Transaction (Month/Day/Year)										Chief Financial Officer							
C/O LIN	11/2	11/26/2024								Chief Financial Officer										
2173 SA	1																			
2173 SALK AVENUE, SUITE 200						4. If Amendment, Date of Original Filed (Month/Day/Year)								6 In	6. Individual or Joint/Group Filing (Check Applicable					
(Ctroot)					7. "/	4. II Amendment, Date of Original Filed (Month/Day/Year)									Line)					
(Street)					1										Form filed by One Reporting Person					
CARLSBAD CA 92008					1										Form filed by More than One Reporting				orting	
,					1									1	Perso	on				
(City)	(8	State) (2	Zip)		1									1						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of	Security (In	tion							ired (A) or	or 5. Amount of				7. Nature					
				Date (Month/Da	v/Year)	Execution Date,			Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			, 4 and	Securi Benefi		Form: D (D) or In		of Indirect Beneficial			
(montangay					(Month/Day/Year)			8)				Owned Followi Reported				Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D) Price		Price	Transaction(s)			- [(111511. 4)	
				Jour	<u> </u>	Amount	(D)		1100	(Instr.	nstr. 3 and 4)									
Common Shares 11/26/20						.024					15,000	A	\ \$	0.59 ⁽¹	2.	5,500	D			
		Ta	hla II -	Derivati	vo Se	Curit	tios A	7 can	ired I	Dien	osed of	or Re	nofi	cially	Owne		,	<u> </u>		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of	2.	3. Transaction	emed	4.		5. Number		6. Date Exercisable and			7. Title and			. Price of	9. Number			11. Nature		
Derivative Security	Conversion or Exercise		Execut if any	Execution Date,		ction Instr.			Expiration Date Amount of (Month/Day/Year) Securities				erivative ecurity	derivative Securities		Ownership Form:	of Indirect Beneficial			
(Instr. 3)) Price of \ (Mont			/Day/Year)	8)		Securities		Underlying				rlying		nstr. 5)	Beneficially	y Dire	Direct (D)	Ownership	
	Derivative Security						Acquired (A) or		Derivative Security (I					str.		Owned Following		or Indirect (I) (Instr. 4)	(Instr. 4)	
						Disposed		3 and 4)					Reported Transaction	- 1'''	,					
				of (D) (Instr.				١							(Instr. 4)	n(s)				
						ànd														
													Amo	unt						
													or Num	ber						
					Code		[, <u>,</u> ,	__	Date Exercisable		Expiration	Tials	of							
					Code	٧	(A)	(D)	Exercis	sable	Date	Title	Shar	es						

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.5925 to \$0.5929, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1.

/s/ Jill A. Howe

11/26/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.